Keyphrases
Acute Lymphoblastic Leukemia
9%
ADAR1
6%
Adenosine Deaminase Acting on RNA
6%
Adoptive Cell Therapy
52%
Adoptive Cell Transfer
21%
Adoptive Immunotherapy
6%
Adoptive Transfer
13%
Adoptive Transfer Therapy
6%
Anti-CD19 chimeric Antigen Receptor T Cells
9%
Anti-melanoma
8%
Antitumor
12%
Autologous Tumors
10%
Autoreactive T Cells
9%
B-cell Malignancies
7%
Carcinoembryonic Antigen
9%
CD19
10%
CD19 chimeric Antigen Receptor T Cells
15%
CD28
11%
CD40
6%
CD8+ T Cells
7%
CEACAM1
16%
Cell Adhesion Molecule 1 (CADM1)
12%
Chimeric Antigen Receptor T Cells (CAR-T)
52%
Chimeric Antigen Receptor T-cell Therapy
16%
Clinical Response
15%
Complete Response
6%
Constitutively Active
9%
Effector Function
8%
Genetic Modification
11%
High-dose interleukin-2
7%
Immune Resistance
6%
Intercellular Adhesion molecule-1 (ICAM-1)
7%
Interferon-α (IFN-α)
6%
Interleukin-2
12%
Ipilimumab
7%
Large B-cell Lymphoma
6%
Lymphocyte Culture
11%
Melanoma
44%
Melanoma Cells
32%
Melanoma Patients
19%
Metastatic Melanoma
51%
MicroRNA
10%
MRNA Electroporation
6%
Normal Human
9%
Overall Survival
6%
Relapsed or Refractory Acute Myeloid Leukemia
7%
T Cell Activation
9%
T Cells
55%
Tumor
11%
Tumor-infiltrating Lymphocytes
100%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
13%
Adoptive Transfer
14%
B-Cell Lymphoma
6%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
13%
Cell Line
5%
Cell Therapy
36%
Chimeric Antigen Receptor
21%
Chimeric Antigen Receptor T-Cell
39%
Chimeric Antigen Receptor T-Cell Immunotherapy
11%
Cytotoxic T-Cell
7%
Disease
9%
Drug Megadose
7%
Immunotherapy
27%
Infusion
9%
Integrin
6%
Interleukin 2
13%
Large-Cell Lymphoma
7%
Leukapheresis
5%
Lymphocyte
7%
Lymphocyte Culture
7%
Lymphocytic Infiltration
5%
Malignant Neoplasm
11%
Melanoma Cell
13%
Metastatic Melanoma
42%
microRNA
7%
Neoplasm
37%
Nodular Melanoma
56%
Overall Survival
6%
Secretion (Process)
6%
T Cell
50%
T Lymphocyte
5%
Transfer Cell
15%
Tumor Infiltrating Lymphocyte
60%
Tumor Necrosis Factor
6%
Immunology and Microbiology
Adenosine Deaminase
6%
Adjuvant
5%
Adoptive Immunotherapy
6%
Antineoplastic Activity
5%
B Cell
14%
Carcinoembryonic Antigen
9%
CD19
27%
CD28
9%
CEACAM1
16%
Cell Adhesion Molecule 1
12%
Cell Line
10%
Chimeric Antigen Receptor
15%
Chimeric Antigen Receptor T-Cell
25%
Chimeric Antigen Receptor T-Cell Therapy
12%
Cytokine
9%
Cytotoxic T-Cell
7%
Cytotoxicity
5%
DNA Modification
7%
Downregulation
5%
Electroporation
7%
Immunity
6%
Immunocompetent Cell
6%
Immunotherapy
36%
interferon
6%
Interleukin 2
12%
Ipilimumab
6%
Lymphocyte
11%
Lymphocyte Culture
7%
Melanoma Cell
33%
Natural Killer Cell
7%
Neoantigen
8%
Normal Human
6%
Overall Survival
6%
Secretion (Process)
10%
T Cell
71%
T Cell Receptor
5%
Transfer Cell
20%
Tumor Cell
5%
Tumor Necrosis Factor
7%
Tumor-Associated Macrophage
17%
Tumor-Infiltrating Lymphocytes
68%